1 tion fraction or use of aspirin or warfarin (Coumadin).

2 ), the target of the anticoagulant warfarin (Coumadin).

3 initially treated with aspirin and then with coumadin.

4 spital discharge, patients were treated with Coumadin and aspirin.

5                                     Aspirin, coumadin, and heparin are often initiated as secondary p

6                                          The Coumadin Aspirin Reinfarction Study (CARS) database cont

7 to dialysis after they were taken off of the coumadin at 6, 12, and 20 months posttransplant because

8 istration changed the labeling for warfarin (Coumadin, Bristol-Myers Squibb, Princeton, New Jersey),

9 ild-type mice treated with the anticoagulant coumadin display increased hepatic bacterial burden and

10                          (Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial

11 BRUISE CONTROL INFECTION (Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial

12 The BRUISE CONTROL trial (Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial)

13 rts that much of the population and warfarin/coumadin patients may not receive sufficient vitamin K f

14 gulated with aspirin and Plavix, Lovenox, or Coumadin, respectively.

15 y induced by chronic anticoagulant (warfarin/coumadin) therapy are all linked to age-associated condi

16  age, sex, APACHE III scores, liver disease, Coumadin treatment, or INR level between those who did a

17         Of the seven 7 patients treated with coumadin, two patients are doing well at 2 and 3 years p

18 f heart failure, baseline heart rate, EF and coumadin use.

19 low-dose oral anticoagulation with warfarin (Coumadin) was equivocal.

20 transplant patients, seven were treated with coumadin, whereas two were treated with heparin.